Study of a Drug to Reduce Bile Viscosity

Interventional Study on the Effect of Bromhexine Hydrochloride on Bile Viscosity Reduction - BBR Study (Bromhexine for Bile Reduction)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041250002

Enrollment

Registered

2025-04-10

Start date

2025-04-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive jaundice caused by hepatobiliary and pancreatic tumors Cholangitis, bile viscosity, mucolytic agent, bromhexine hydrochloride

Interventions

Drug Name: Bromhexine Hydrochloride Dosage: 4 mg, three times daily after meals Administration Route: Oral Duration: 7 consecutive days

bile viscosity

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults aged 20 years or older Patients with biliary drainage tubes placed externally Patients without cholangitis (diagnosed based on Tokyo Guidelines 2018) Patients capable of oral intake and able to take bromhexine hydrochloride Written informed consent obtained

Exclusion criteria

Exclusion criteria: Known allergy to bromhexine hydrochloride Severe liver or kidney dysfunction Pregnant or breastfeeding women Other patients deemed unsuitable for the study by the principal investigator

Design outcomes

Primary

Measure	Time frame
Change in bile viscosity(mPa s) before and after intervention	—

Secondary

Measure	Time frame
Mucin content in bile(mcg/ml) before and after intervention	—

Contacts

Public ContactYusuke Nimura

Nagoya University Graduate School of Medicine

nimura.yusuke.i6@f.mail.nagoya-u.ac.jp+81-52-741-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026